JP2020519669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519669A5 JP2020519669A5 JP2019563191A JP2019563191A JP2020519669A5 JP 2020519669 A5 JP2020519669 A5 JP 2020519669A5 JP 2019563191 A JP2019563191 A JP 2019563191A JP 2019563191 A JP2019563191 A JP 2019563191A JP 2020519669 A5 JP2020519669 A5 JP 2020519669A5
- Authority
- JP
- Japan
- Prior art keywords
- pellet according
- ethyl cellulose
- weight
- release coating
- hpmc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008188 pellet Substances 0.000 claims 21
- 239000001856 Ethyl cellulose Substances 0.000 claims 10
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 10
- 229920001249 ethyl cellulose Polymers 0.000 claims 10
- 235000019325 ethyl cellulose Nutrition 0.000 claims 10
- 239000011248 coating agent Substances 0.000 claims 8
- 238000000576 coating method Methods 0.000 claims 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 7
- 239000002702 enteric coating Substances 0.000 claims 5
- 238000009505 enteric coating Methods 0.000 claims 5
- 208000029560 autism spectrum disease Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229960001157 acamprosate calcium Drugs 0.000 claims 3
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 229920006318 anionic polymer Polymers 0.000 claims 2
- 229920003086 cellulose ether Polymers 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 229920001169 thermoplastic Polymers 0.000 claims 2
- 239000004416 thermosoftening plastic Substances 0.000 claims 2
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023073242A JP7499539B2 (ja) | 2017-05-17 | 2023-04-27 | ホモタウリンおよびその塩の製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507532P | 2017-05-17 | 2017-05-17 | |
| US62/507,532 | 2017-05-17 | ||
| US201862660690P | 2018-04-20 | 2018-04-20 | |
| US62/660,690 | 2018-04-20 | ||
| PCT/US2018/033205 WO2018213589A1 (en) | 2017-05-17 | 2018-05-17 | Formulations of homotaurines and salts thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023073242A Division JP7499539B2 (ja) | 2017-05-17 | 2023-04-27 | ホモタウリンおよびその塩の製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020519669A JP2020519669A (ja) | 2020-07-02 |
| JP2020519669A5 true JP2020519669A5 (enExample) | 2021-07-26 |
Family
ID=64274653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563191A Pending JP2020519669A (ja) | 2017-05-17 | 2018-05-17 | ホモタウリンおよびその塩の製剤 |
| JP2023073242A Active JP7499539B2 (ja) | 2017-05-17 | 2023-04-27 | ホモタウリンおよびその塩の製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023073242A Active JP7499539B2 (ja) | 2017-05-17 | 2023-04-27 | ホモタウリンおよびその塩の製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12042566B2 (enExample) |
| EP (1) | EP3624788A4 (enExample) |
| JP (2) | JP2020519669A (enExample) |
| KR (1) | KR20200005576A (enExample) |
| AU (2) | AU2018269557B2 (enExample) |
| CA (1) | CA3062834A1 (enExample) |
| IL (1) | IL270654B2 (enExample) |
| WO (1) | WO2018213589A1 (enExample) |
| ZA (1) | ZA201908264B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL270654B2 (en) | 2017-05-17 | 2024-07-01 | Confluence Pharmaceuticals Llc | Formulations of homotaurines and salts thereof |
| WO2025163673A1 (en) * | 2024-01-29 | 2025-08-07 | Micro Labs Limited | Dose-dumping resistant tablets of acamprosate calcium |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01280192A (ja) | 1988-10-25 | 1989-11-10 | Nichibei Co Ltd | ブラインド内装サッシ |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| PE57198A1 (es) | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| US6514530B2 (en) | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| CA2328197C (en) | 1998-04-14 | 2007-11-20 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| WO2000018374A1 (en) | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
| ES2168043B1 (es) | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| RU2375048C2 (ru) | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
| DE102004023069A1 (de) | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| CA2504471A1 (en) * | 2004-06-18 | 2005-12-18 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| DE102007009243A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| JP2010532331A (ja) | 2007-07-05 | 2010-10-07 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 抗痙攣医薬組成物 |
| US9463172B2 (en) | 2009-02-12 | 2016-10-11 | Indiana University Research & Technology Corporation | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9195775B2 (en) | 2009-06-26 | 2015-11-24 | Iii Holdings 2, Llc | System and method for managing and/or rendering internet multimedia content in a network |
| US20110142889A1 (en) | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| CA2850468C (en) * | 2010-09-28 | 2019-08-13 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
| ES2665569T3 (es) | 2011-03-01 | 2018-04-26 | Pharnext | Tratamiento de la isquemia cerebral |
| MX2021000431A (es) | 2011-03-23 | 2022-10-28 | Ironshore Pharmaceuticals & Dev Inc | Metodos y composiciones para el tratamiento de trastorno por deficit de atencion. |
| KR20130002292A (ko) | 2011-06-28 | 2013-01-07 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| US20130143867A1 (en) * | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| AU2013293167B2 (en) | 2012-07-22 | 2019-04-18 | Indiana University Research And Technology Corporation | Modulation sAPP, sAPP alpha and BDNF levels in individuals diagnosed with FXS and ASD |
| US20140073678A1 (en) | 2012-09-12 | 2014-03-13 | Monosol Rx, Llc | Anti-pain and anti-nausea and/or vomiting combinatorial compositions |
| CN105431144A (zh) | 2013-06-05 | 2016-03-23 | 思康脑侒股份有限公司 | 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合 |
| SG11201606275WA (en) * | 2014-02-11 | 2016-08-30 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| IL255343B2 (en) * | 2015-05-04 | 2024-10-01 | Confluence Pharmaceuticals Llc | Sprinkle formulations of acamprosate |
| EP3331518A4 (en) | 2015-08-04 | 2019-04-03 | Confluence Pharmaceuticals, LLC | COMBINATION THERAPY WITH ACAMPROSATE AND D-CYCLOSERIN |
| JP6066009B1 (ja) | 2016-06-16 | 2017-01-25 | 富士電機株式会社 | ガス絶縁開閉装置用操作器及びそれを用いたガス絶縁開閉装置 |
| IL270654B2 (en) | 2017-05-17 | 2024-07-01 | Confluence Pharmaceuticals Llc | Formulations of homotaurines and salts thereof |
-
2018
- 2018-05-17 IL IL270654A patent/IL270654B2/en unknown
- 2018-05-17 EP EP18802495.4A patent/EP3624788A4/en active Pending
- 2018-05-17 KR KR1020197035170A patent/KR20200005576A/ko not_active Ceased
- 2018-05-17 CA CA3062834A patent/CA3062834A1/en active Pending
- 2018-05-17 AU AU2018269557A patent/AU2018269557B2/en active Active
- 2018-05-17 US US16/612,877 patent/US12042566B2/en active Active
- 2018-05-17 JP JP2019563191A patent/JP2020519669A/ja active Pending
- 2018-05-17 WO PCT/US2018/033205 patent/WO2018213589A1/en not_active Ceased
-
2019
- 2019-12-11 ZA ZA2019/08264A patent/ZA201908264B/en unknown
-
2021
- 2021-08-31 AU AU2021225172A patent/AU2021225172B2/en active Active
-
2023
- 2023-04-27 JP JP2023073242A patent/JP7499539B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019147832A5 (enExample) | ||
| JP2009502487A5 (enExample) | ||
| JP2009545560A5 (enExample) | ||
| JP2009502969A5 (enExample) | ||
| JP2012236837A5 (enExample) | ||
| KR20110081316A (ko) | 디아세레인 함유 약제학적 조성물 | |
| JP2012153724A5 (enExample) | ||
| JP2010511663A5 (enExample) | ||
| JP2019513800A5 (enExample) | ||
| CA2651716A1 (en) | Duloxetine hydrochloride delayed release formulations | |
| RU2014101227A (ru) | Композиция покрытия, подходящая для фармацевтических или нутрицевтических лекарственных форм | |
| CN101431986A (zh) | 固体剂型调配物 | |
| CN103784414B (zh) | 一种埃索美拉唑肠溶片及其制备方法 | |
| US20090004284A1 (en) | Controlled release tamsulosin hydrochloride formulation | |
| US20140178468A1 (en) | Multiparticulate extended-release composition of mesalamine | |
| US20110052687A1 (en) | Extended release pharmaceutical composition of paliperidone | |
| RU2018137359A (ru) | Пероральные фармацевтические композиции месалазина | |
| JP2020519669A5 (enExample) | ||
| RU2008136766A (ru) | Таблетки метопролола сукцината пролонгированного действия и способы их приготовления | |
| JP2005306778A (ja) | 徐放性製剤及びその製造方法 | |
| CN1213301A (zh) | 丙戊酸金属盐缓释片剂 | |
| RU2015138784A (ru) | Фармацевтическая композиция в виде мультичастиц, содержащая множество гранул двух видов | |
| CA2797042A1 (en) | Fingolimod in the form of a solid solution | |
| ITFI20100175A1 (it) | Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system). | |
| JP2019513801A5 (enExample) |